文献速递淋巴瘤

克拉屈滨联合利妥昔单抗治疗变异型毛细胞白血病的长期随访:II期研究最终结果

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
PubMed 文献 · Blood Adv · 2021-01-01

该II期研究纳入20例变异型毛细胞白血病(HCLv)患者,接受克拉屈滨联合利妥昔单抗(CDAR)治疗,完全缓解率达95%,6个月时80%患者骨髓MRD转阴。中位随访69.7个月,5年无进展生存率和总生存率分别为63.3%和73.9%,TP53突变者预后较差,6个月MRD阴性完全缓解与更长生存显著相关。

要点

  • CDAR方案在HCLv中完全缓解率达95%,6个月骨髓MRD阴性率80%。

核心结论

  • CDAR方案对HCLv有效,达到MRD阴性完全缓解者结局更佳。

研究设计与样本

  • II期研究纳入20例HCLv患者,其中8例既往未治疗,接受克拉屈滨0.15 mg/kg第1-5天联合利妥昔单抗375 mg/m2每周一次共8次。

主要发现

  • 完全缓解率为95%(95%CI 75-100),6个月时16/20例(80%,95%CI 56-94)骨髓MRD转阴。
  • MRD阴性完全缓解的中位持续时间为70.1个月,16例中7例至120个月仍MRD阴性。
  • 中位随访69.7个月,11例接受延迟利妥昔单抗,5年PFS和OS分别为63.3%和73.9%。

临床怎么用

  • CDAR可作为HCLv的有效治疗方案,尤其适用于追求MRD阴性完全缓解的患者。
  • 治疗6个月评估骨髓MRD状态有助于预后分层。
  • TP53突变患者预后较差,需密切监测。

局限性

  • 样本量小(20例),为单臂II期研究,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term outcomes are unknown. We report final results of a phase 2 study of CDAR for patients with HCLv. Twenty patients with 0 to 1 prior courses of cladribine and/or rituximab, including 8 who were previously untreated, received cladribine 0.15 mg/kg on days 1 to 5 with 8 weekly rituximab doses of 375 mg/m2 beginning day 1. Patients received a second rituximab course ≥6 months after cladribine, if and when minimal residual disease (MRD) was detected in blood. The complete remission (CR) rate from CDAR was 95% (95% confidence interval, 75-100). Sixteen (80%) of 20 patients (95% confidence interval, 56-94) became MRD negative according to bone marrow at 6 months. The median duration of MRD-negative CR was 70.1 months, and 7 of 16 are still MRD negative up to 120 months. With a median follow-up of 69.7 months, 11 patients received delayed rituximab, and the 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 73.9%, respectively. Five patients with TP53 mutations had shorter PFS (median, 36.4 months vs unreached; P = .0024) and OS (median, 52.4 months vs unreached; P = .032). MRD-negative CR at 6 months was significantly associated with longer PFS (unreached vs 17.4 months; P < .0001) and OS (unreached vs 38.2 months; P < .0001). Lack of MRD in blood at 6 months was also predictive of longer PFS and OS (P < .0001). After progression following CDAR, median OS was 29.7 months. CDAR is effective in HCLv, with better outcomes in patients who achieve MRD-negative CR. This trial is registered at www.clinicaltrials.gov as #NCT00923013.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chihara D, Arons E, Stetler-Stevenson M, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021. PMID: 34607348. doi:10.1182/bloodadvances.2021005039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。